Cited by 526Chromatin Remodeling and CancerPARP inhibition in cancer therapyDNA Repair Mechanisms

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Open access

Shen, Jianfeng, Peng, Yang, Wei, Leizhen, Zhang, Wei, Yang, Lin, Lan, Li, Kapoor, Prabodh, Ju, Zhenlin, Mo, Qianxing, Shih, Ie-Ming, Uray, Ivan P., Wu, Xiangwei, Brown, Powel H., Shen, Xuetong, Mills, Gordon B., Peng, Guang·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-14-0849PMC PMC4497871

Published version of a preprint

Open this paper in CoChat — free account

Abstract

ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors. Significance: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors. Cancer Discov; 5(7); 752–67. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 681

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-14-0849

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes
Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798

Show all 61 references

Sorted by citations

ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Self-citation
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 972
Self-citation
Advances in bladder cancer biology and therapy
Tran, L. L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 758
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 727
Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618
Current recommendations and recent progress in endometrial cancer
Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., Son, C. H., Tatebe, K., & Veneris, J. T. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21561 · Cited by 594
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 544
Regulation of Single-Strand Annealing and its Role in Genome Maintenance
Bhargava, R., Onyango, D. O., & Stark, J. M. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.06.007 · Cited by 512
Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
Heeke, A. L., Pishvaian, M. J., Lynce, F. C., Xiu, J., Brody, J. R., Chen, W.-J., Baker, T. M., Marshall, J. L., & Isaacs, C. J. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00286 · Cited by 477
Integrated Molecular Characterization of Uterine Carcinosarcoma
Cherniack, A. D., Shen, H., Walter, V., Stewart, C., Murray, B. A., Bowlby, R., Hu, X., Ling, S., Soslow, R. A., Broaddus, R. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.010 · Cited by 440
Self-citation
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 434
Systemic therapies for intrahepatic cholangiocarcinoma
Kelley, R. K., Bridgewater, J. A., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 406
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Secrier, M., Li, X., de Silva, N., Eldridge, M., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O’Donovan, M., Miremadi, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 402
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C., & Chan, H. M. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.07.011 · Cited by 400
PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers
Pilie, P. G., Gay, C. M., Byers, L. A., O’Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 343
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 292
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update)
Oscanoa, J., Sivapalan, L., Gadaleta, E., Ullah, A. Z. M. D., Lemoine, N. R., & Chelala, C. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa420 · Cited by 275
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
Lissanu, Y., Sun, Y., Terranova, C. J., Khan, F., Martínez-Ledesma, E., Gay, J. P., Gao, G., Mullinax, R. A., Khor, T. O., Feng, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0019-5 · Cited by 268
SWI/SNF Complex–deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract
Agaimy, A., Daum, O., Märkl, B., Lichtmannegger, I., Michal, M., & Hartmann, A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000554 · Cited by 242
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V. P., McIntyre, C. A., Dika, I. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 247
Targeting ARID1A mutations in cancer
Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury, A., Hall, S., Curtin, N. J., & Drew, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107450 · Cited by 180
Endometrial cancer: Molecular markers and management of advanced stage disease
Arend, R. C., Jones, B. A., Martínez, A., & Goodfellow, P. J. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.015 · Cited by 180
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 168
Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities
Pierre, R. S., & Kadoch, C. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.004 · Cited by 165
Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy
Wanior, M., Krämer, A., Knapp, S., & Joerger, A. C. (2021) · Oncogene · doi:10.1038/s41388-021-01781-x · Cited by 162
ARID1A loss in cancer: Towards a mechanistic understanding
Mathur, R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.001 · Cited by 161
Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer
Yen, T., Wang, T., Fader, A. N., Shih, I., & Gaillard, S. L. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000585 · Cited by 167
Self-citation
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Alessi, J. V., Ricciuti, B., Spurr, L. F., Gupta, H. V., Li, Y. Y., Glass, C., Nishino, M., Cherniack, A. D., Lindsay, J. R., Sharma, B., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.024 · Cited by 156
Aurora kinase A, a synthetic lethal target for precision cancer medicine
Mou, P. K., Yang, E. J., Shi, C., Ren, G., Tao, S., & Shim, J. S. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00635-6 · Cited by 150
Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells
Wu, C., Lyu, J., Yang, E. J., Liu, Y., Zhang, B., & Shim, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-05694-4 · Cited by 136
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
Saito, M., Suzuki, H. Y., Kono, K., Takenoshita, S., & Kohno, T. (2017) · Surgery Today · doi:10.1007/s00595-017-1497-7 · Cited by 135
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy
Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S. L., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 138
Self-citation
ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer
Li, L., Li, M., Jiang, Z., & Wang, X. (2019) · Cells · doi:10.3390/cells8070678 · Cited by 122
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Chabanon, R. M., Morel, D., Eychenne, T., Daage, L. C., Bajrami, I., Dorvault, N., Garrido, M., Meisenberg, C., Lamb, A. E., Duong-Ngo, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0628 · Cited by 120
Epigenomic regulation of oncogenesis by chromatin remodeling
Kumar, R., Li, D.-Q., Müller, S., & Knapp, S. (2016) · Oncogene · doi:10.1038/onc.2015.513 · Cited by 117
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 123
The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts
Vélez-Cruz, R., & Johnson, D. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081776 · Cited by 121
SWI/SNF: Complex complexes in genome stability and cancer
Ribeiro-Silva, C., Vermeulen, W., & Lans, H. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.03.007 · Cited by 110
R Loops and Their Composite Cancer Connections
Wells, J. P., White, J., & Stirling, P. C. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.08.006 · Cited by 111
Biology of Melanoma
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 115
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
Wang, L., Yang, L., Wang, C., Wei, Z., Ju, Z., Zhang, W., Shen, J., Peng, Y., An, C., Luu, Y. T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130445 · Cited by 106
Self-citation
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Cao, W., Ma, X., Fischer, J. V., Sun, C., Kong, B., & Zhang, Q. H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00301-z · Cited by 104
Chromatin remodellers as therapeutic targets
Malone, H. A., & Roberts, C. W. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00978-5 · Cited by 119
ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
Caumanns, J. J., Wisman, G. B. A., Berns, K., van der Zee, A. G. J., & de Jong, S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.005 · Cited by 102
Epigenetic modifiers: activities in renal cell carcinoma
de Cubas, A. A., & Rathmell, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0052-7 · Cited by 97
Medical treatment for cholangiocarcinoma
Adeva, J., Sangro, B., Salati, M., Edeline, J., Casta, A. L., Bittoni, A., Berardi, R., Bruix, J., & Valle, J. W. (2019) · Liver International · doi:10.1111/liv.14100 · Cited by 97
Targeting the replication stress response through synthetic lethal strategies in cancer medicine
Ngoi, N. Y. L., Pham, M. M., Tan, D. S. P., & Yap, T. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.06.002 · Cited by 95
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
Self-citation
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Muckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 95
Detect accessible chromatin using ATAC-sequencing, from principle to applications
Sun, Y., Miao, N., & Sun, T. (2019) · Hereditas · doi:10.1186/s41065-019-0105-9 · Cited by 92
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Mandal, J., Mandal, P., Wang, T.-L., & Shih, I.-M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00856-5 · Cited by 84
Self-citation
ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas
Wang, W., Friedland, S. C., Guo, B., O’Dell, M. R., Alexander, W. B., Whitney‐Miller, C. L., Agostini‐Vulaj, D., Huber, A. R., Myers, J. R., Ashton, J. M., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315541 · Cited by 96
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead
Aslan, M., Shahbazi, R., Ulubayram, K., & Özpolat, B. (2018) · Anticancer Research · doi:10.21873/anticanres.13026 · Cited by 92
PARP Inhibitors Resistance: Mechanisms and Perspectives
Giudice, E., Gentile, M., Salutari, V., Ricci, C., Musacchio, L., Carbone, M. V., Ghizzoni, V., Camarda, F., Tronconi, F., Nero, C., et al. (2022) · Cancers · doi:10.3390/cancers14061420 · Cited by 95
Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
Miller, R. E., Brough, R., Bajrami, I., Williamson, C. T., McDade, S. S., Campbell, J., Kigozi, A., Rafiq, R., Pemberton, H. N., Natrajan, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0554 · Cited by 89
Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review
Samartzis, E. P., Labidi‐Galy, S. I., Moschetta, M., Uccello, M., Kalaitzopoulos, D. R., Fidalgo, J. A. P., & Boussios, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3022a · Cited by 83
Landscape of EBV-positive gastric cancer
Saito, M., & Kono, K. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01215-3 · Cited by 86
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
Morel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 87
Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance
Suenaga, M., Yu, J., Shindo, K., Tamura, K., Almario, J. A., Zaykoski, C., Witmer, P. D., Fesharakizadeh, S., Borges, M., Lennon, A.-M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2463 · Cited by 81
The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
Xu, S., & Tang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745187 · Cited by 87
International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group
Cho, K. R., Cooper, K., Croce, S., Djordevic, B., Herrington, C. S., Howitt, B. E., Hui, P., Ip, P. P. C., Köbel, M., Lax, S., et al. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000496 · Cited by 80
Self-citation
Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance
Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 79
Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract
Agaimy, A., Bertz, S., Liang Cheng, C., Hes, O., Junker, K., Keck, B., Antonio Lopez-beltran, B., Stöckle, M., Wullich, B., & Hartmann, A. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1977-y · Cited by 77
ARID2 modulates DNA damage response in human hepatocellular carcinoma cells
Oba, A., Shimada, S., Akiyama, Y., Nishikawaji, T., Mogushi, K., Ito, H., Matsumura, S., Aihara, A., Mitsunori, Y., Ban, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.026 · Cited by 73
DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
Hsiehchen, D., Hsieh, A., Samstein, R. M., Lu, T., Beg, M. S., Gerber, D. E., Wang, T., Morris, L. G. T., & Zhu, H. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100034 · Cited by 75
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
Khalique, S., Naidoo, K., Attygalle, A. D., Kriplani, D., Daley, F. M., Lowe, A., Campbell, J., Jones, T., Hubank, M. J. F., Fenwick, K., et al. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.103 · Cited by 75
The impact of ARID1A mutation on molecular characteristics in colorectal cancer
Tokunaga, R., Xiu, J., Goldberg, R. M., Philip, P. A., Seeber, A., Battaglin, F., Arai, H., Lo, J. H., Naseem, M., Puccini, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.006 · Cited by 71
Self-citation
Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma
Xing, T., Li, L., Chen, Y., Ju, G., Li, G., Zhu, X., Ren, Y., Zhao, J., Cheng, Z., Li, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101264 · Cited by 78
Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01523-4 · Cited by 76
ARID1A regulates R-loop associated DNA replication stress
Tsai, S., Chang, E. Y., Fournier, L.-A., Wells, J. P., Minaker, S. W., Zhu, Y. D., Wang, A. Y.-H., Wang, Y., Huntsman, D. D., & Stirling, P. C. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009238 · Cited by 75
Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability
Jäkel, C., Bergmann, F., Toth, R., Assenov, Y., van der Duin, D., Strobel, O., Hank, T., Klöppel, G., Dorrell, C., Grompe, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01118-x · Cited by 69
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
Zhao, W., Li, J., Chen, M.-J. M., Luo, Y., Ju, Z., Nesser, N. K., Johnson-Camacho, K., Boniface, C. T., Lawrence, Y., Pande, N. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.008 · Cited by 68
Self-citation
Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
Fan, Y., Zhu, X., Xu, Y., Lu, X., Xu, Y., Wang, M., Xu, H., Ding, J., Ye, X., Fang, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1582 · Cited by 66
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
Banerjee, S. N., Stewart, J., Porta, N., Toms, C., Leary, A. F., Lheureux, S., Khalique, S., Tai, J., Attygalle, A. D., Vroobel, K. M., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002973 · Cited by 66
Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma
Zhu, C., Xu, Z., Zhang, T., Qian, L., Xiao, W., Wei, H., Jin, T., & Zhou, Y. Y. (2021) · Journal of Cancer · doi:10.7150/jca.53395 · Cited by 65
Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex‐deficient cancers
Sasaki, M., & Ogiwara, H. (2020) · Cancer Science · doi:10.1111/cas.14311 · Cited by 62
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Schettini, F., Giudici, F., Bernocchi, O., Sirico, M., Corona, S. P., Giuliano, M., Locci, M., Paris, I., Scambia, G., Placido, S. D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.035 · Cited by 65
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Concannon, K., Morris, B. B., Gay, C. M., & Byers, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.031 · Cited by 71
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
Post, C., Westermann, A. M., Bosse, T., Creutzberg, C. L., & Kroep, J. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102973 · Cited by 64
Resolving DNA Damage: Epigenetic Regulation of DNA Repair
Karakaidos, P., Karagiannis, D., & Rampias, T. N. (2020) · Molecules · doi:10.3390/molecules25112496 · Cited by 64
ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells
Sen, M., Wang, X., Hamdan, F. H., Rapp, J., Eggert, J., Kosinsky, R. L., Wegwitz, F., Kutschat, A. P., Younesi, F. S., Gaedcke, J., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0690-5 · Cited by 61
SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract: Clinicopathologic Study of 30 Cases With an Emphasis on Variable Morphology, Immune Features, and the Prognostic Significance of Different SMARCA4 and SMARCA2 Subunit Deficiencies.
Chang, B., Sheng, W., Wang, L., Zhu, X., Tan, C., Ni, S., Weng, W., Huang, D., & Wang, J. (2022) · PubMed · doi:10.1097/pas.0000000000001836 · Cited by 24
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
Dillon, M. T., Guevara, J., Mohammed, K., Patin, E. C., Smith, S. A., Dean, E. J., Jones, G. N., Willis, S. E., Petrone, M., Silva, C. J. R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci175369 · Cited by 69
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Devarakonda, S. H. K., Sankararaman, S., Herzog, B. H., Gold, K. A., Waqar, S. N., Ward, J. P., Raymond, V. M., Lanman, R. B., Chaudhuri, A. A., Owonikoko, T. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0879 · Cited by 61
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma
Schallenberg, S., Bork, J., Essakly, A., Alakus, H., Buettner, R., Hillmer, A. M., Bruns, C. J., Schroeder, W., Zander, T., Loeser, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-019-6425-3 · Cited by 61
Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy
Zhang, F.-L., & Li, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112815 · Cited by 63
ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response
Bakr, A., Corte, G., Veselinov, O., Kelekçi, S., Chen, M.-J. M., Lin, Y.-Y., Sigismondo, G., Iacovone, M., Cross, A., Syed, R., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae233 · Cited by 71
The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks
Harrod, A., Lane, K. A., & Downs, J. A. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102919 · Cited by 60
Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
Lin, X., Chen, D., Zhang, C., Zhang, X., Li, Z., Dong, B., Gao, J., & Shen, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0790-7 · Cited by 59
SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancerPreprint
Tordella, L., Khan, S. S., Hohmeyer, A., Banito, A., Klotz, S., Raguz, S., Martin, N., Dhamarlingam, G., Carroll, T. D., González-Meljem, J. M., et al. (2016) · Genes & Development · doi:10.1101/gad.286112.116 · Cited by 57
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
Booth, L. A., Roberts, J. L., Sander, C., Lee, J., Kirkwood, J. M., Poklepovic, A. S., & Dent, P. (2017) · Oncotarget · doi:10.18632/oncotarget.14829 · Cited by 58
ATR Is a Therapeutic Target in Synovial Sarcoma
Jones, S. E., Fleuren, E. D. G., Frankum, J. R., Konde, A., Williamson, C. T., Krastev, D. B., Pemberton, H. N., Campbell, J., Gulati, A., Elliott, R. J. R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2056 · Cited by 61
Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression
Jana, S., Brahma, S., Arora, S., Wladyka, C. L., Hoang, P., Blinka, S. M., Hough, R. P., Horn, J. L., Liu, Y., Wang, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.021 · Cited by 57
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
Auguste, A., Genestie, C., de Bruyn, M., Adam, J., Formal, A. L., Drusch, F., Pautier, P., Crosbie, E. J., MacKay, H. J., Kitchener, H. C., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0055-1 · Cited by 56
Molecular-targeted therapies and precision medicine for endometrial cancer
Mitamura, T., Dong, P., Ihira, K., 工藤, 正., & Watari, H. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy159 · Cited by 56

Authors: Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., Uray, I. P., Wu, X., Brown, P. H., Shen, X., Mills, G. B., & Peng, G.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
University of Pittsburgh (US)
Baylor College of Medicine (US)
Johns Hopkins University (US)
1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author: Peng, Guang
ORCID: Shen, Jianfeng
Peng, Yang
Zhang, Wei
Yang, Lin
Lan, Li
Ju, Zhenlin
Mo, Qianxing
Shih, Ie-Ming
Wu, Xiangwei
Brown, Powel H.
Mills, Gordon B.
Peng, Guang
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-07-01
Volume: 5
Issue: 7
Pages: 752-767
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-14-0849
PMC: PMC4497871
OpenAlex: W2123454509
Cited by: 522
References: 61
Citations by year: 2026: 33 · 2025: 53 · 2024: 59 · 2023: 56 · 2022: 53 · 2021: 71 · 2020: 62 · 2019: 43 · 2018: 36 · 2017: 28 · 2016: 24 · 2015: 3
FWCI: 13.16
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (CA 016672, P50CA098258, P50-CA83639, R00CA149186, K99CA149186, P50CA083639, P30CA016672, R01CA181663)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords: ARID1A, SWI/SNF complex, DNA damage checkpoint, PARP inhibitors, ATR kinase, DNA double-strand breaks, tumor suppressor, drug sensitivity
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Breast Neoplasms, DNA Damage, DNA-Binding Proteins, Female, Humans, Lung Neoplasms, Male, Nuclear Proteins, Transcription Factors, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Mice, DNA Breaks, Double-Stranded, Ataxia Telangiectasia Mutated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks